“…12) On the other hand, we reported recently that (i) two sulfated lipids [sulfatide and cholesterol-3-sulfate (CH-3S), SCS] highly stimulate the phosphorylation of several SCSbinding proteins (SCS-BPs), such as high mobility group protein 1 (HMG1), 13) bovine FGF-binding protein (FGF-BP), 14) and p5 (N-terminal 28 amino acid residues of acidic FGF-BP), 15) by casein kinase 1 (CK1) in vitro; and (ii) the direct binding of SCS to these basic proteins causes them to undergo conformational changes, which presumably facilitate their high phosphorylation by CK1 in vitro. [13][14][15] However, there is no report concerning the effect of meFucoidan on the physiological functions of these SCS-BPs involved in the inflammatory responses. Therefore, the present study was carried out to determine (i) the inhibitory effect of meFucoidan, in comparison with two sulfated compounds (heparin and sulfatide), on the activities of sPLA 2 -IIA and pancreatic PLA 2 (pPLA 2 ); (ii) the binding affinity of meFucoidan with four functional basic proteins (sPLA 2 -IIA, bFGF, histone H2B and Hcore 164B) and four synthetic FGF-BP peptides (sp5, GE13, RS6 and RS6 variant) containing potent phosphorylation sites for cAMP-dependent protein kinase (A-kinase); and (iii) the inhibitory effect of meFucoidan on the A-kinase-mediated phosphorylation of these substrate peptides in vitro.…”